Kura Oncology (NASDAQ:KURA) Given “Outperform” Rating at Wedbush

Kura Oncology (NASDAQ:KURA)‘s stock had its “outperform” rating restated by research analysts at Wedbush in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $36.00 price objective on the stock. Wedbush’s price target would suggest a potential upside of 254.68% from the stock’s current price.

Several other analysts have also weighed in on the stock. Oppenheimer set a $24.00 price objective on shares of Kura Oncology in a report on Thursday, May 28th. Citizens Jmp reaffirmed a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a research note on Monday, June 15th. Wall Street Zen raised Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday, May 16th. CLSA set a $24.00 price target on Kura Oncology in a research note on Thursday, June 4th. Finally, Jefferies Financial Group set a $24.00 price target on shares of Kura Oncology in a report on Thursday, May 28th. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $25.46.

Kura Oncology Price Performance

NASDAQ KURA opened at $10.15 on Tuesday. The company has a market cap of $901.02 million, a P/E ratio of -3.03 and a beta of 0.35. The company has a fifty day simple moving average of $10.30 and a 200 day simple moving average of $9.28. Kura Oncology has a 1 year low of $5.45 and a 1 year high of $12.49. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.05. The business had revenue of $18.27 million during the quarter, compared to analyst estimates of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. On average, sell-side analysts predict that Kura Oncology will post -3.45 EPS for the current year.

Insider Transactions at Kura Oncology

In related news, insider Mollie Leoni sold 84,929 shares of the stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total transaction of $834,002.78. Following the completion of the transaction, the insider directly owned 182,345 shares of the company’s stock, valued at approximately $1,790,627.90. This represents a 31.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Suvretta Capital Management LLC increased its position in shares of Kura Oncology by 5.7% during the 4th quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company’s stock worth $89,099,000 after purchasing an additional 459,422 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Kura Oncology by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock valued at $57,224,000 after buying an additional 39,105 shares during the last quarter. Armistice Capital LLC boosted its holdings in shares of Kura Oncology by 5.7% in the 4th quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock valued at $51,285,000 after buying an additional 264,000 shares during the last quarter. State Street Corp grew its stake in shares of Kura Oncology by 47.5% in the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after buying an additional 1,587,959 shares in the last quarter. Finally, AQR Capital Management LLC increased its holdings in Kura Oncology by 36.6% during the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after buying an additional 820,020 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.